
Sign up to save your podcasts
Or


James Gregson, our newly appointed UK Life Sciences and Healthcare leader, joins our episode host Samrina Bhatti, to share his thoughts on what's next for the industry. James talks about his leadershipstyle and what makes a good leader as well as his views on digital transformation,collaboration and developing talent in the Life Sciences and Healthcare industry.
Visit our Life Sciences Connect Podcast homepage to discover more episodes.
What lies ahead for patients, your organisation and your workforce? In this podcast, we explore our predictions for the life sciences and health care industry in 2025, how the pandemic has accelerated industry trends and what this means for you.
Our host Karen Taylor, who leads Deloitte Centre for Health Solutions, speaks to Hanno Ronte, Life Sciences and Healthcare leader Monitor Deloitte, Shivani Maitra, in our Future of Work team, and Sara Siegel, Public Sector Healthcare lead.
This episode explores:
C-suite leaders in pharmaceutical companies increasingly view Real World Evidence (RWE) as strategically important. RWE enables R&D organisations to prioritise their pipeline investments more effectively, better understand underlying causes of disease and identify opportunities for indication expansion and business development.
In the sixth episode of Life Sciences Connect, we explore the role of Real World Evidence in providing insights into existing diagnostic and treatment pathways, identifying unmet need and demonstrating the clinical and economic impact of interventions within the healthcare system.
This episode is led by our host Karen Taylor. Karen is joined by Meri Petrovsca, the Knowledge Management Director at AstraZeneca and Seb Burnett, the General Manager of ConvergeHEALTH by Deloitte Europe.
This episode explores:
Healthcare systems across Europe face rising pressures – particularly the increasing healthcare needs due to growing and ageing populations, multi-morbidity, and public expectations of more personalised and convenient services. Many clinicians are struggling to cope with increasing workloads, and the gap between the supply of resources and the demand for healthcare is widening. Consequently, most countries are looking to digital transformation to close this gap but progress has largely been slow, and the digital maturity of providers, both within and between countries, varying widely.
While COVID-19 has accelerated technology adoption and all countries can point to examples of good practice, there is scope for lessons to be learned more widely and for many of the alliances and partnerships that have been established over the past few months to become a driver of new models of outcome based care and shape a more predictive, preventative, personalised and participatory future.
Our survey respondents of some 1800 clinicians across seven countries identified that the top challenges in implementing digital technologies were bureaucracy in healthcare, the cost of technology and finding the right technologies. Despite the challenges that lie ahead, our surveyed clinicians felt increasingly positive about the adoption of digital technologies.
In the fifth episode of Life Sciences Connect, we explore the challenges facing digital transformation in European healthcare, how things have been changing as a result of COVID-19 and how we should proceed into the future.
The Biotech sector is a key player in driving biopharma innovation and developing ground-breaking treatments for patients. Supporting the growth of this sector is vital to ensure that R&D efforts continue, both now and in the future. However, like most industries, this sector faces a complex set of challenges.
Over the past six months, the biotech sector has rapidly pivoted to respond to the challenge of the COVID-19 pandemic. Companies have grappled with this new reality by adapting to a new way of working and by forging new partnerships across the sector. In the next six months, companies will need to navigate the challenges associated with Brexit including planning for possible workforce related issues and a possible new regulatory environment.
In the fourth episode of Life Sciences Connect, we explore the challenges and opportunities facing the Biotech Industry.
The COVID-19 pandemic has brought the Life Sciences Industry to an inflection point. It has exposed the limitations of traditional linear supply chain models, highlighted the need for sustainability and accelerated the move towards digital transformation.
Will the COVID-19 pandemic act as a catalyst for biopharma companies to recognise their vulnerabilities and accelerate the digital transformation of their global supply chain models?
In the third episode of Life Sciences Connect, we explore the digital transformation of the biopharma supply chain and adoption of AI powered technology.
In the second episode of Life Sciences Connect, we explore how the COVID-19 pandemic has accelerated the move towards the Future of Health, where technology and data enable health care that is more personalised, predictive, preventative and participatory.
Life Sciences Connect is the brand new podcast brought to you by the Deloitte Centre for Health Solution. Each month, we will connect with industry experts and leaders from the Biotech, Pharmaceutical and Medical Devices industries to discuss how key trends, explored in our research reports, are charting a new, sustainable future for the Life Sciences Industry.
For our first episode, we explore the use of AI technology in clinical trials and how the COVID-19 pandemic is promoting the use of advanced technologies within the biopharma industry.
This episode is led by our host Karen Taylor. Karen is joined by Fiona Maini, Principal Global Science and Compliance at Medidata, and Fareed Melham, Head of Acorn AI Labs at Medidata Solutions.
This episode covers:
From the publisher's feed

980 Listeners